Abstract
We gave intravenous amrinone to 40 patients in heart failure, and oral amrinone to 18 patients. Acute intravenous administration caused a significant reduction in mean blood pressure and this was severe enough to require correction by plasma infusion in five patients. Oral amrinone was accompanied by thrombocytopenia in 10 patients but no complications were associated with the low platelet count. Other potentially serious adverse effects were: abdominal pain (two patients), nausea and vomiting (three patients), jaundice (one patient), myositis (one patient), pulmonary infiltrates (two patients), and polyserositis (one patient). Less serious adverse effects observed were: splenomegaly, eosinophilia, fever, headache, reduced tear secretion, dry skin, and nail discoloration. The potentially severe adverse reactions with amrinone need to be weighed carefully against its benefits in the treatment of heart failure.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Benotti J. R., Grossman W., Braunwald E., Davolos D. D., Alousi A. A. Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med. 1978 Dec 21;299(25):1373–1377. doi: 10.1056/NEJM197812212992501. [DOI] [PubMed] [Google Scholar]
- Endoh M., Yamashita S., Taira N. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. J Pharmacol Exp Ther. 1982 Jun;221(3):775–783. [PubMed] [Google Scholar]
- Honerjäger P., Schäfer-Korting M., Reiter M. Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence. Naunyn Schmiedebergs Arch Pharmacol. 1981 Dec;318(2):112–120. doi: 10.1007/BF00508835. [DOI] [PubMed] [Google Scholar]
- Kullberg M. P., Dorrbecker B., Lennon J., Rowe E., Edelson J. High-performance liquid chromatographic analysis of amrinone and its N-acetyl derivative in plasma. Pharmacokinetics of amrinone in the dog. J Chromatogr. 1980 Jan 4;187(1):264–270. doi: 10.1016/s0021-9673(00)87899-1. [DOI] [PubMed] [Google Scholar]
- LeJemtel T. H., Keung E., Ribner H. S., Davis R., Wexler J., Blaufox J. D., Sonnenblick E. H. Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure. Am J Cardiol. 1980 Jan;45(1):123–129. doi: 10.1016/0002-9149(80)90229-5. [DOI] [PubMed] [Google Scholar]
- LeJemtel T. H., Keung E., Sonnenblick E. H., Ribner H. S., Matsumoto M., Davis R., Schwartz W., Alousi A. A., Davolos D. Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man. Circulation. 1979 Jun;59(6):1098–1104. doi: 10.1161/01.cir.59.6.1098. [DOI] [PubMed] [Google Scholar]
- Rubin S. A., Lee S., O'Connor L., Hubenette A., Tober J., Swan H. J. Thrombocytopenia and fever in a patient taking amrinone. N Engl J Med. 1979 Nov 22;301(21):1185–1185. doi: 10.1056/NEJM197911223012118. [DOI] [PubMed] [Google Scholar]
- Siegel L. A., Keung E., Siskind S. J., Forman R., Feinberg H., Strom J., Efstathakis D., Sonnenblick E. H., LeJemtel T. H. Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure. Circulation. 1981 Apr;63(4):838–844. doi: 10.1161/01.cir.63.4.838. [DOI] [PubMed] [Google Scholar]
- Wilmshurst P. T., Thompson D. S., Jenkins B. S., Coltart D. J., Webb-Peploe M. M. Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. Br Heart J. 1983 Jan;49(1):77–82. doi: 10.1136/hrt.49.1.77. [DOI] [PMC free article] [PubMed] [Google Scholar]